Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Our cancer strategy is powered by cutting-edge technologies and ... FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent (dupilumab), Libtayo, Praluent (alirocumab), ...

cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Do not use if you are allergic to dupilumab or to any of the ...

Ebglyss, the third biologic targeting IL-13 for atopic dermatitis, follows Dupixent (dupilumab) and Adbry/Adtralza (tralokinumab ... Imdelltra (tarlatamab-dlle) developed by Amgen|small-cell lung ...

cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Do not use if you are allergic to dupilumab or to any of the ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab ... for extensive-stage small cell lung cancer (ES-SCLC). Using Amgen's bispecific T cell ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new ... Sanofi/Regeneron's Dupixent (dupilumab) and LEO Pharma's Adbry/Adtralza (tralokinumab). According to Clarivate ...

The division will have responsibility for Sanofi's underperforming cancer R&D unit that was revamped ... including arthritis therapy sarilumab and dupilumab for asthma. Two key objectives for ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals ... metastatic non-small cell lung cancer and ulcerative colitis. It is based on VelocImmune technology. It was under development ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the ... of 3.49% during 2024-2034. Advanced Pancreatic Cancer Market: The 7 major advanced pancreatic cancer markets are expected to ...